Navigation Links
Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
Date:12/22/2009

ant (p=0.34), the difference in mortality between the high-dose group and placebo was 6.7%.

The greatest benefit was observed in the population at the highest risk of mortality as assessed by APACHE II Predicted Risk of Mortality (PROM). In patients who were considered at higher risk of death, mortality among placebo patients was 56.3% versus 33.3% in high-dose patients (p=0.105).

About ACCESS

Based on the trial results, Eisai is now conducting a global Phase III clinical trial program, called ACCESS (A Controlled Comparison of Eritoran tetrasodium and Placebo in Patients with Severe Sepsis). The trial will further evaluate eritoran as a potential treatment for severe sepsis, the second most frequent cause of death in intensive care patients in the U.S., surpassed only by cardiovascular events. In the European Union (EU), sepsis is the most common cause of death in the ICU.

The ACCESS trial population will enroll substantially more patients than the Phase II trial and has been sized (n=2,000) to determine the efficacy (reduction in 28-day all-cause mortality) of eritoran and targets a population with severe sepsis that has a moderate-to-high risk of mortality as determined by baseline APACHE II (Acute Physiology and Chronic Health Evaluation II) scores from 21 to 37. APACHE II is a severity of illness scoring system commonly used in sepsis research and ICUs.

About Eritoran, TLR4 and Severe Sepsis

Sepsis is a condition involving infection and inflammation. The body's normal response to an infection is to initiate an immunological chain reaction of inflammation. In severe sepsis, systemic inflammation may be an overreaction leading to injury and failure of one or more organ systems that may become life-threatening. The toll-like receptor 4 (TLR4) is part of the innate immune system and, when it is activated, TLR4 may play an important role
'/>"/>

SOURCE Eisai
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
3. American Imaging Managements New Specialty Drug Program Delivers Immediate Results
4. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
5. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
6. Immucor to Announce Fiscal Second Quarter Financial Results on Wednesday, January 6, 2010
7. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
10. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
11. Neogen Corporation Announces 2nd Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015  Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" ... on developing, manufacturing, and acquiring cutting-edge technology, products and ... will be exhibiting at booth # 709 at the ... (NAPNAP) taking place on March 11-13, 2015 at Caesars ... The 36 th annual NAPNAP ...
(Date:3/5/2015)... , March 5, 2015   AMC ... management solutions recognized for improving the effectiveness and ... that Robert Anazagasty and Jared ... serve as Vice President, Strategic Client Development, and ... These additions support AMC Health,s commitment to accelerating ...
(Date:3/5/2015)...  Celsion Corporation (NASDAQ: CLSN ) ... conference call to discuss year-end 2014 financial results ... for ThermoDox®, its proprietary heat-activated liposomal encapsulation of ... and TheraSilence™, in immunotherapy and RNA delivery at ... To participate in the call, interested parties may ...
Breaking Medicine Technology:Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2
... WORCESTER, Mass. and TORONTO, Nov. 21, 2011 Generex ... that its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ... its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide ... the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium ...
... Calif., Nov. 21, 2011  BARRX Medical Inc., a leader ... with endoscopy to remove precancerous tissue from the gastrointestinal ... agreement to be acquired by Covidien.  Covidien is a ... leader in advanced energy-based devices.  Covidien ...
Cached Medicine Technology:Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 2Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 3Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 4Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 5BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3
(Date:3/5/2015)... Sunrise, FL (PRWEB) March 05, 2015 ... appear at this week’s Arnold Sports Festival and ... March 5-8. Metabolic Nutrition will host a display ... its all-new pre-workout E.S.P. and its highly-popular, class-leading fat ... free shaker cups, unique recipes that utilize its top-of-the-line ...
(Date:3/5/2015)... Think it’s tough to get kids to ... them to brush their teeth. That’s a finding from a ... Delta Dental(1) in conjunction with National Parenting Month in March. ... kids to brush their teeth is one of the most ... higher than getting children to eat vegetables regularly (42 percent) ...
(Date:3/5/2015)... DE (PRWEB) March 05, 2015 The ... false weight loss promises is alarming, with more and ... products without an actual prescription, making it easy for ... that simply take their money and endanger their health. ... questions before purchasing prescription online diet pills: , 1.    Where ...
(Date:3/5/2015)... The MTC 5-day Fundamental Implantology Course ... from a variety of dental disciplines, to offer implant ... "From the onset we wanted this course to be ... to the excellence of the lecturers and the sheer ... more than satisfied our aims." , Unlike large-scale ...
(Date:3/5/2015)... Plains, NY (PRWEB) March 05, 2015 Hope ... New York Sporting Clay Shoot to be held at Beretta ... May 15, 2015. All proceeds from the event will benefit ... a sense of self, restoring the family unit, and restoring ... The event will honor our nation’s heroes through a day ...
Breaking Medicine News(10 mins):Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3Health News:MIS Global Training Center (MTC) Launches its Fundamental Implantology Course for Doctors - with a Difference 2Health News:Hope For The Warriors Announces New York Clay Shoot to Benefit Military Families 2
... by the National Human Genome Research Institute (NHGRI), has ... shows promise in laboratory studies for treating a fatal ... ,These drugs belong to a class of farnesyltransferase inhibitors ... myeloid leukemia, neurofibromatosis and other conditions. It could also ...
... Brisk walks or running may reduce the risk of ovarian cancer, ... may reduce the risk of some other forms of cancer. ... a 70 % reduction in the risk of development of ovarian ... colon cancer was also less frequent among those who exercised. ...
... behaviors, like over speeding, more in company of same ... sex. ,The study was published on-line edition of ... ,The findings indicate that teen risky driving increases in ... But more important, the finding should remind teens-and the ...
... from University of Pennsylvania had identified a brain chemical ... abuse. The chemical called orexin is also involved in ... ,Research showed that the activation of ... that controls many vital functions such as eating, body ...
... couples trying to conceive that is, one in every six ... a problem with conception. ,With this being the clinical ... is increasing day by day. // In spite of ... to physical, mental and psychological trauma. Anxiety of patients regarding ...
... by AUT Professor of Nutrition Elaine Rush states that ... sugar as well as caffeine contributes to obesity. // ... containing sugar, added caffeine and guarana (which also contains ... more rapidly than lemonade. "These results could have huge ...
Cached Medicine News:Health News:Brain Chemical Identified For Drug Dependent Behavior 2Health News:Will anxiety regarding fertility treatment affect the chances of conception? 2Health News:Obesity Can Be Caused By Consumption Of Energy Drinks 2
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
For the quantitative in vitro determination of Triglycerides in serum and plasma....
CK-MB Control...
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
Medicine Products: